Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Definium Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 84 | 1 | 93 | +10 |
| Shares | 3.89M | 218 | 3.88M | −13.5K (−0.3%) |
| Value | $13.9M | $779 | $12.1M | −$1.75M (−12.6%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Definium Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 193,882 | $606.9K | 0.00% |
| Citigroup Inc | 87,095 | $272.6K | 0.00% |
| Citadel Advisors LLC | 61,688 | $193.1K | 0.00% |
| Jump Financial, LLC | 34,000 | $106.4K | 0.00% |
| Virtu Financial LLC | 28,494 | $89.0K | 0.01% |
| Rathbone Brothers plc | 25,000 | $78.3K | 0.00% |
| GTS Securities LLC | 19,854 | $62.1K | 0.00% |
| Commonwealth Equity Services, LLC | 16,951 | $53.0K | 0.00% |
| Jane Street Group, LLC | 16,584 | $52.2K | 0.00% |
| Regal Investment Advisors LLC | 14,556 | $45.6K | 0.00% |
| Marshall Wace, LLP | 11,545 | $36.1K | 0.00% |
| Simplex Trading, LLC | 9,735 | $30.0K | 0.00% |
| Qube Research & Technologies Ltd | 9,005 | $28.2K | 0.00% |
| Toronto Dominion Bank | 2,557 | $8.00K | 0.00% |
| Householder Group Estate & Retirement Specialist, LLC | 300 | $939 | 0.00% |
| Creative Planning | 218 | $683 | 0.00% |
| Tower Research Capital LLC (TRC) | 133 | $416 | 0.00% |
| Robbins Farley LLC | 28 | $88 | 0.00% |
| VisionPoint Advisory Group, LLC | 16 | $50 | 0.00% |
Sold out (9)
Institutions that held Definium Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Alyeska Investment Group, L.P. | 796,962 | $2.85M |
| Renaissance Technologies LLC | 36,519 | $130.0K |
| Freestone Capital Holdings, LLC | 11,497 | $41.0K |
| Moisand Fitzgerald Tamayo, LLC | 2,000 | $7.14K |
| Clearview Wealth Advisors LLC | 66 | $236 |
| Northwestern Mutual Wealth Management Co | 33 | $118 |
| NewSquare Capital LLC | 17 | $61 |
| Assetmark, Inc | 8 | $29 |
| Horan Securities, Inc. | 2 | $7 |
Not filed for Q3 2023 yet (1)
Institutions that held Definium Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Kistler-Tiffany Companies, LLC | 218 | $779 |